Investor Relations

Juno Therapeutics is building a fully integrated biopharmaceutical company focused on developing innovative cellular immunotherapies for the treatment of cancer. Founded on the vision that the use of human cells as therapeutic entities will drive one of the next important phases in medicine, Juno is developing cell-based cancer immunotherapies based on chimeric antigen receptor and high-affinity T cell receptor technologies to genetically engineer T cells to recognize and kill cancer. Juno is developing multiple cell-based product candidates to treat a variety of B-cell malignancies as well as multiple solid tumors and multiple myeloma. Several product candidates have shown compelling clinical responses in clinical trials in refractory leukemia and lymphoma conducted to date. Juno's long-term aim is to leverage its cell-based platform to develop new product candidates that address a broader range of cancers and human diseases. 

There are no items to display.
Date Title and Summary
Toggle Summary Leading Cancer Research Centers Team up to Launch Biotech Startup Focused on Cancer Immunotherapy
Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute join together to launch Juno Therapeutics Inc. Company founded with $120M initial investment, among largest fully committed Series A for a biotech startup in
Toggle Summary Juno Announces New Investments, Leadership Appointments
SEATTLE, Jan. 13, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a new biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today an expanded Series A including Bezos Expeditions, the personal investment company of Jeff Bezos, and leading venture capital
Toggle Summary Juno Therapeutics Appoints Biotech Investment Banking Leader Steve Harr as CFO and Head of Corporate Development
SEATTLE , March 31, 2014 /PRNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, announced today that Steve Harr , M.D., will join the company as its Chief Financial Officer and Head of Corporate Development.
Toggle Summary Juno Completes $176M Series A Round
SEATTLE , April 24, 2014 /PRNewswire-USNewswire/ -- Juno Therapeutics, a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced the close of its Series A round with $176M in fully committed funds. Juno's initial funding of $120 million came predominantly

UPCOMING & PAST EVENTS

View all events

Copyright Nasdaq. Minimum 15 minutes delayed.